EMMA Stock — Emmaus Life Sciences Inc

Emmaus Life Sciences Inc (EMMA)

Updated October 9, 2026.

EMMA is a Stock. Its deepest 1-year drawdown was 49.2%.

Emmaus Life Sciences is a biopharmaceutical company that discovers, develops, and commercializes treatments for rare and orphan diseases. Its primary marketed product is Endari, an oral L-glutamine therapy for reducing acute complications of sickle cell disease, and it holds licensing rights to an IRAK4 inhibitor candidate for various cancers. The company does not currently distribute dividends to shareholders.

EMMA performance

Returns are updating. EMMA's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 49.2%.

EMMA key facts

Asset type

Stock

Asset class

Equity

Inception date

08/22/1996

Distribution frequency

None

Last close

$0.04 (stale; as of 2026-10-09)

Market cap

$3,004,058

Average volume

26055.0

Payment date

07/18/2019

Beta

9.768

Payout ratio

0.0%

Forward P/E

11.9048

EPS

$-0.09

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

EMMA risks and drawbacks

The deepest 1-year drawdown on record here is 49.2%.

Who may consider EMMA — and who may not

It is a weaker fit for investors who need monthly cash flow (EMMA does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on EMMA

• All tickers starting with E

Tagged: Healthcare.

Frequently asked questions